All In Biotech

Drug Trial Radar · NCT07185477

A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

May 31, 2027

Study completion May 31, 2028

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of GPRC5D/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with relapsed/refractory multiple myeloma (RRMM).

Conditions

  • Relapsed/Refractory Multiple Myeloma (RRMM)

Interventions

  • QLS32015Biological

    QLS32015 is a GPRC5D × CD3 bispecific antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Minimum 2 years after infusion
  2. Safety and TolerabilityTime frame: Minimum 2 years after infusion

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.